Connect with us

Headlines

Ocugen Plans $53M Public Offering

The company seeks to commercialize gene therapies to cure blindness diseases.

mm

Published

on

MALVERN, PA — Ocugen Inc. announced the pricing of its underwritten public offering of nearly 16 million shares of common stock.

Gross proceeds are expected to be about $53.5 million before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ocugen (Nasdaq: OCGN). The offering is expected to close on or about Feb. 25, subject to customary closing conditions.

In addition, Ocugen has granted to the underwriter a 30-day option to purchase up to about 2.4 million additional shares of its common stock.

Ocugen intends to use the net proceeds from the offering for “general corporate purposes, capital expenditures, working capital and general and administrative expenses,” according to a press release.

Ocugen is focused on “discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19.”

According to the company: “Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – ‘one to many’ and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.”

Advertisement

SPONSORED VIDEO

SPONSORED BY VARILUX

The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Advertisement

Most Popular